

BioFluidica: Advancing Personal Medicine

Rolf Muller, Ph.D.
CEO of BioFluidica, Inc.

DATE: Wednesday, January 17, 2018

TIME: 6:00 PM Social Hour, Light Dinner
7:00 PM Lecture

PLACE: Committee Lecture Hall, The Scripps Research Institute
10596 North Torrey Pines Road
La Jolla, CA 92037

RSVP: January 15, 2018
<https://biofluidica.eventbrite.com>



ABOUT THE SPEAKER:

Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrix, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris, France.

ABOUT THE PRESENTATION:

How a small San Diego Biotech Company can make a difference in the future of the \$233 billion Personalized Medicine market.

BioFluidica has invented a ground-breaking diagnostic platform for vastly improved disease detection from blood samples. Diagnostic tests include capture and analysis of viable circulating tumor cells, cell-free DNA, and exosomes with unprecedented recovery, purity, throughput, and cost savings, thereby enabling large-scale cancer diagnoses from liquid biopsies (blood samples). The platform has been clinically validated on six cancer-including solid tumor- and blood-based cancers.

The presentation will not only focus on the technical aspect of the platform development, including instrumentation engineering, software development, chemical engineering, molecular and cellular biology and polymer science, but will also give insight on how to scale an early stage research tool to clinical performance.